Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14246768 | 0.82 | PRSS12 (0.70) | TAS1R3TAS1R1LMNAKMT2AALDH1A1 | |
| SCHEMBL701314 | 0.76 | TAS1R3 (1.00) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| SCHEMBL11748653 | 0.72 | KMT2A (0.67) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| SCHEMBL11746591 | 0.72 | KMT2A (0.70) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| SCHEMBL11746602 | 0.72 | KMT2A (0.70) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| SCHEMBL24334864 | 0.71 | HTT (0.68) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| SCHEMBL15824830 | 0.71 | HTT (0.68) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| SCHEMBL703637 | 0.71 | TAS1R3 (1.00) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL11745237 | 0.71 | KMT2A (0.68) | TAS1R3TAS1R1LMNAKMT2AMEN1 | |
| SCHEMBL11271580 | 0.70 | KMT2A (0.64) | TAS1R3TAS1R1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| EP-2720695-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NoNO Inc. (CA) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | TAS1R3 2049/4885TAS1R1 2229/4885LMNA 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.